Physician profile
Daniel Dat Nguyen
NPI 1952759748
$14,258.01
in general payments reported to CMS, 2019-2025
33 companies · $3,690 in 2025
The $3,690 reported for 2025 was more than what 92% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $767 · 2021: $1,608 · 2022: $2,589 · 2023: $2,101 · 2024: $3,503 · 2025: $3,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,098 · Travel and Lodging: $3,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,097.89 |
| Travel and Lodging | $3,195.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $2,317.57 | 2023-2025 | Evoke, Evoke Scs |
| Nevro Corp. | $1,876.14 | 2022-2024 | Senza |
| Boston Scientific Corporation | $1,136.43 | 2020-2025 | Intracept, General - Pain Management |
| Medtronic, INC. | $1,134.20 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Activa PC |
| Lilly USA, LLC | $1,110.04 | 2021-2023 | Olumiant, Taltz |
| Si-Bone, INC. | $800.61 | 2025 | |
| Janssen Biotech, INC. | $780.18 | 2021-2023 | Tremfya, Stelara |
| Mml US, INC. | $769.75 | 2024-2025 | Reactiv8 |
| Vertos Medical, INC. | $698.07 | 2022-2024 | Mild Device Kit |
| Biotronik Nro, INC. | $634.69 | 2025 | Prospera |
| Globus Medical, INC. | $616.49 | 2025 | Senza |
| Nalu Medical, INC. | $503.98 | 2022-2025 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $420.21 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.38 | 2023-2025 | Relistor |
| Galderma Laboratories, L.P. | $188.31 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zynex Medical, INC. | $162.70 | 2023 | Nexwave |
| Painteq LLC | $162.18 | 2023-2024 | Painteq |
| Novartis Pharmaceuticals Corporation | $112.87 | 2022 | |
| Janssen Scientific Affairs, LLC | $105.61 | 2021 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Tersera Therapeutics LLC | $70.45 | 2022-2024 | Prialt |
| Abbott Laboratories | $56.39 | 2023-2025 | Aveir, Proclaim, Jot Dx |
| Amgen INC. | $52.11 | 2022 | |
| Biotronik INC. | $43.09 | 2025 | |
| Spr Therapeutics, INC | $43.06 | 2025 | Sprint Pns System |
| Idorsia Pharmaceuticals US INC | $32.95 | 2023-2024 | Quviviq |
| Averitas Pharma INC. | $29.14 | 2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $24.97 | 2025 | |
| Bioventus LLC | $22.77 | 2023 | Durolane |
| Valinor Pharma, LLC | $18.48 | 2025 | Movantik |
| Kowa Pharmaceuticals America, INC. | $15.52 | 2023 | Seglentis |
| Abbvie INC. | $13.52 | 2023 | |
| Stimwave Technologies Incorporated | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.